Clinical Trial: A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta(R) in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386938) titled 'A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta(R) in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer' on Jan. 28.

Brief Summary: The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta(R) in combination with trastuzumab and docetaxel as the 1st line therapy for patients with HER2-positive breast cancer (BC). Secondary Purposes are to evaluate the pharmacokinetics of RPH-051 in comparison with Perjeta(R) after a single-dose and repeated intraven...